Tofacitinib

This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...

This update is important because tofacitinib is a JAK inhibitor approved for adults with moderately to severely active ulcerative colitis after inadequate response to TNF blockers, and the label includes major safety...

FDA drug-label updates change how a medicine should be used and monitored. For people with ulcerative colitis and other immune-mediated diseases, this label highlights safety risks and limits on combining tofacitinib...

This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.

Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...

This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...

An FDA DailyMed label update directly affects prescribing information and safety warnings for tofacitinib, a drug used in ulcerative colitis and other immune-mediated diseases. Patients and clinicians should be aware of...

This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...

The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.